Protein Fluidics is commercializing assay automation platforms using our novel microfluidic technologies in order to accelerate data driven decisions in the Life Sciences. We are passionate about providing scientists with the latest tools to help them create the next generation of therapeutics. The company is located in the San Francisco Bay Area and run by an experienced team of scientists, engineers, and industry executives. It is privately held and has closed three rounds of funding from strategic investors.
Evan F Cromwell, PhD
President & CEO
Evan has over 30 years of senior executive and technical expertise in numerous hi-tech industries. He has piloted the design, development, and manufacture of systems for biological assays, materials analysis, optical inspection, and process control. Prior to Protein Fluidic, Evan served as the President and CEO of California-based Blueshift Biotechnologies. This high-content screening and analysis venture was acquired by Molecular Devices in 2008. After the acquisition, Evan remained onboard at Molecular Devices, which became part of Danaher Life Sciences, where he further honed his business and entrepreneurial acumen. In addition to co-founding successful start-ups, Evan has chaired several scientific advisory boards and led global technology development initiatives. Evan’s passion is integrating new technologies into products that provide unexpected value to customers in life sciences and other communities.
Evan holds a B.S. in Chemistry from Caltech and earned his Ph.D. in Physical Chemistry in the laboratory of Nobel Laureate Yuan-Tseh Lee at the University of California, Berkeley. He has authored 40+ publications in the fields of biology, physical chemistry, and optical instrumentation and holds 17 patents.
Byungrae Cho, PhD
Director of Product Devlopment
Byungrae is a creative and innovative bioengineer and team leader of product development at Protein Fluidics. He has over 10 years of engineering experience in research, bioinstrumentation, and microfluidics. He has been involved in research and development of bioassay instrumentation for both basic biological sciences and clinical diagnostics. Byungrae started his career in South Korea in the BioTechnology Group at Samsung as a mechanical engineer before coming to University of California Berkeley to pursue his PhD in bioengineering. He has had roles at Fluidigm in microfluidic device development and Thermo Fisher Scientific in Clinical NextGen Sequencing before joining Protein Fluidics.
Byungrae holds a B.S. and M.S in Mechanical Engineering from Seoul National University and a Ph.D. in Bioegnineering from University of California, Berkeley.
Sean R Morrison
Sean Morrison is Director of the Children’s Medical Center Research Institute (CRI) at UT Southwestern Medical Center. He is a Howard Hughes Medical Institute Investigator and member of the National Academy of Medicine. He is known for his significant discoveries in stem cell biology and cancer. His laboratory studies the mechanisms that maintain stem cell function in adult tissues and the ways in which cancer cells hijack these mechanisms to enable tumor formation. A better understanding of these mechanisms offers the potential to yield new regenerative medicine and cancer therapies.
He earned a bachelor’s degree in biology and chemistry from Dalhousie University in Canada and a Ph.D. in immunology at Stanford University. He completed a postdoctoral fellowship in neurobiology at Caltech and directed the University of Michigan’s Center for Stem Cell Biology. Sean was a Searle Scholar, and received the Presidential Early Career Award for Scientists and Engineers, the International Society for Hematology and Stem Cells McCulloch and Till Award , the American Association of Anatomists Harland Mossman Award (2008), and a MERIT Award from the National Institute on Aging. He is a past President of the International Society of Stem Cell Research.
David Piston is the Edward Mallinckrodt, Jr. Professor and Head of Cell Biology and Physiology at Washington University School of Medicine in St Louis, Missouri. His research focuses on glucagon regulation and uses innovative quantitative imaging and biochemical methods to identify new therapeutic targets in type 1 and type 2 diabetes. Prior to Washington University he was a Faculty member at Vanderbilt University where his lab focused on the question of how the syncytium of insulin-secreting beta cells works as a unit to optimally regulate blood sugar in an animal, and the mechanisms by which those cells know that they are part of the syncytium. During this time he developed novel biosensors and imaging techniques such as hyperspectral light sheet microscopy for fast, simultaneous imaging of multiple biosensors.
He earned a bachelor’s degree in physics at Grinnell College and a Ph.D. in physics at University of Illinois at Urbana–Champaign. He did postdoctoral studies in applied physics at Cornell University. He is currently serving as President of the Biophysical Society.
Hong has 25+ years of ingenuity in creating novel tools for the life sciences, medical device, data storage, and telecom industries. He has put his expertise to use by leading various R & D teams in analytical chemistry, microfluidics, robotics, and instrumentation. In 2011, Hong founded the Berkeley-based venture HJ Science & Technology (HJST) as a conduit for the rapid prototyping and commercialization of microscale automation-based technology. HJST excels in creating innovative, real-time portable tools that rival accepted industry standards. HJST-based platforms have diverse applications from life sciences and medical diagnostics, to analytical chemistry and environmental monitoring. Their current research priorities include immunoassays, synthetic biology, analytical chemistry, and genetic screening. Protein Fluidics has licensed key HJST technologies.
Hong has a B.S. in Engineering Physics from University of California, Berkeley, an M.S. in Applied Physics from Caltech, and a Ph.D. in Physics from MIT. He has won several federally-funded SBIR and technology grants from a wide range of agencies such as the DOA, DoD, EPA, NASA, and NSF.
Nicholas J Colella
Nicholas J. Colella, PhD is Managing Partner at Incubic Management, LLC, funding and advising technology ventures, including Aurrion, Greystripe, MBio Diagnostics, Precision Photonics, Protein Fluidics, ThinGap, and Quintessent. He served as Senior Vice President, Intermolecular, discovering materials for customers and executing a turn-around (2016-17). He has held senior executive roles at Tessera (Xperi) ( 2001-06), PolyStor Corporation (2000-01), and Angel Technologies (1995-2000). At Lawrence Livermore National Laboratory, 1986-96, he led missile defense programs, invented a missile defense architecture, and co-founded nChip, an electronics spinout acquired by Flextronics. He served on Corporate Boards of Grandis, (acquired by Samsung), Ultracell (sold to Brentronics), and on the Science Advisory Board of Zyvex. He co-founded the National Robotics Engineering Center, Carnegie Mellon, 1995-96, and served as first Advisory Board Chairman.
He earned a B.A. in Honors Physics from Temple University, where he is an Alumni Fellow, and served on its Board of Visitors, College of Science and Technology. He holds a M.S. and Ph.D. in Physics, Carnegie Mellon. He completed business, and executive programs at UCLA, Carnegie Mellon, Stanford, and Caltech.
December 4, 2018 Protein Fluidics partners with BioLegend to provide Assay Products
May 4, 2018 Protein Fluidics announces the Pu·MA system
October 1, 2016 Protein Fluidics moves into new headquarters in Burlingame, CA
April 6, 2016 Protein Fluidics closes Series seed round of investment